-
HEOR Theater - External Control Arms – The Case for a Standardized Lexicon and Toolkit
10:00AM - 10:45AM EST
-
10 November: Use of Propensity Scores in Observational Studies of Treatment Effects
In observational research, issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities.
-
Health Preferences in HTA: Use of Patient and Public Preferences
-
HEOR Theater - Addressing Prenatal Exposures and Outcomes for Regulatory Requirements Using Real-World Data
1:00PM - 1:45PM EST
-
HEOR Theater - Effect Modification in Network Meta-Analysis: Is Population Adjustment Always the Answer?
12:00PM - 12:45PM EST
-
HEOR Theater - Optimizing Research Using Real-World Data During the COVID-19 Pandemic
11:00AM - 11:45AM EST
-
Signal - Episode 5- On-demand until November 30
Join Tom Cassels and Alyssa Jaffe - seasoned venture capital investors with background from the healthcare settings - in discussing the highlights, possible implications and learnings from investment activity for the downstream healthcare decision-making where stakeholders are looking primarily at evidence-based solutions.
-
Evolving Real World Data/Evidence Guidelines and Landscape in China: From Policy to Practice
-
6-7 October: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element.
-
Health Preference Research in the Context of Gene Therapy in Rare Diseases
-
27-28 September: Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved.
-
HEOR Theater - Using Item Banks to Build Condition Specific Static Short Form Outcome Measures
1:00PM - 1:45PM EST
-
HEOR Theater - Health Technology Assessment in 2030: How Methods, Technology and Data will Change the Way Drugs are Reimbursed
12:00PM - 12:45PM EST
-
HEOR Theater - Making the most of the NICE methods updates to optimize evidence generation and global HTA strategy
10:00AM - 10:45AM EST
-
Embedded Clinical Trials: Understanding the Opportunities and Challenges for Real-World Evidence Generation
11:00AM - 12:00PM EST
-
Innovations in Value Communication: Optimizing Payer Engagement at the Local Level
11:00AM - 12:00PM EST
-
31 August: Developing Decision-Grade Real-World Evidence
In this course, participants will be guided through a hands-on analysis of real-world data (RWD) to develop decision-grade real-world evidence (RWE) that could be used to support an indication expansion.
-
ISPOR Educational Webinar: The Health Preference Research Landscape - Preference Information, Methods, and Use
-
Use of External Controls for Oncology RWE Studies to Enhance Development and Accelerate Knowledge of New Treatments
-
11-12 August: Applied Cost-Effectiveness Modeling with R
This course is designed to teach clinicians and new researchers how to incorporate health economics into study design and data analysis.